SCHEDULE: Janus Henderson Boosts Janux Therapeutics Stake
Beneficial Ownership Disclosure
Janus Henderson Group PLC has increased its beneficial ownership in Janux Therapeutics, Inc. to 7.5% of common stock, as disclosed in an amended Schedule 13G filing.
Summary
- Janus Henderson Group PLC, a global asset manager, has filed an Amendment No. 2 to its Schedule 13G, indicating its beneficial ownership in Janux Therapeutics, Inc.
- The firm now beneficially owns an aggregate of 4,460,332 shares of Janux Therapeutics' common stock.
- This represents 7.5% of the total class of common stock outstanding.
- Janus Henderson Group PLC holds shared voting and dispositive power over these shares.
- JHIUS, an indirect subsidiary of Janus Henderson, is deemed the beneficial owner of 4,379,232 shares, representing 7.4% of the class.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook. It reflects an investment position.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a significant passive investment by a major institutional asset manager, Janus Henderson Group PLC, in Janux Therapeutics, Inc. Such filings are routine disclosures for investors holding more than 5% of a company's stock, reflecting their investment positions rather than operational or strategic changes within the issuer's industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially influencing market perception of the stock's institutional support.
- Company Management: Awareness of a large, passive institutional holder, though typically without direct influence on control.
Key Dates
| Date | Description |
|---|---|
| 12/09/2022 | Date of Power of Attorney execution for SEC filings by Janus Henderson Group PLC. |
| 06/30/2025 | Date of event which requires filing of this statement. |
| 08/14/2025 | Date of filing and signature by Janus Henderson Group PLC. |
Keywords
Janux Therapeutics, Janus Henderson Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.